Suma Krishnan sold $7.7M of KRYS
President, R&D at Krystal Biotech, Inc.. 25,000 shares at an average of $308.11, traded Jun 4, 2026, filed Jun 5, 2026.
Score components
- +20RolePresident
- +25Trade size$7.7M at market
- 0Share of holdings soldSold 1.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001298711-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -320 | $300.75 | $96k | 1,402,835 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -593 | $302.25 | $179k | 1,402,242 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -247 | $303.17 | $75k | 1,401,995 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $304.89 | $122k | 1,401,595 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -480 | $305.87 | $147k | 1,401,115 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,348 | $307.09 | $414k | 1,399,767 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -12,729 | $307.81 | $3.9M | 1,387,038 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -3,803 | $308.89 | $1.2M | 1,383,235 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,801 | $309.95 | $868k | 1,380,434 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,039 | $310.94 | $634k | 1,378,395 | Jun 5, 2026 |
| Jun 4, 2026 | SOpen-market sale Common Stock10b5-1 | -240 | $311.65 | $75k | 1,378,155 | Jun 5, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 50Moderate | KRYSsell Krystal Biotech, Inc. | Dino A Rossi director | $8.2M 25,000 shares | -33% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% | |
| 7Weak | Krystal Biotech, Inc. | Kathryn Romano Chief Accounting Officer | $201k 750 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.